{"id":5946,"date":"2025-10-30T13:20:31","date_gmt":"2025-10-30T12:20:31","guid":{"rendered":"https:\/\/www.msd.ch\/en\/?post_type=story&p=5946"},"modified":"2025-10-30T13:20:32","modified_gmt":"2025-10-30T12:20:32","slug":"we-support-breast-cancer-awareness-month","status":"publish","type":"story","link":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/","title":{"rendered":"In October we support Breast Cancer Awareness Month"},"content":{"rendered":"\n
\n
\n \n \n Our team<\/small>\n <\/a>\n \n \n

\n In October we support Breast Cancer Awareness Month\n <\/h1>\n

Did you know breast cancer is the most common cancer in women? At MSD, we show solidarity with those facing breast cancer and do everything we can to support further advances to help fighting the disease. Especially during Breast Cancer Awareness Month October we support various activities to educate about the importance of prevention and early detection. Learn more about our commitment.<\/p>\n <\/div>\n\n

\n

30.10.2025<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"Banner:\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n
<\/div>\n\n\n\n

In Switzerland, around 6,600 women and 60 men are diagnosed with breast cancer every year. Although new therapies have improved the prognosis of patients with breast cancer, around 1400 women still die from the disease in Switzerland every year.<\/p>\n\n\n\n

“We stand united for the mothers, sisters, daughters and loved ones impacted by breast cancer and do everything we can to drive further innovation to help save and improve lives.” <\/em><\/p>\n\n\n\n

As with many other cancers, the earlier breast cancer is detected, the better the chances of a cure. <\/strong>That\u2019s why we support various initiatives to raise awareness!<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Awareness campaign in the Pink Cube<\/strong><\/p>\n\n\n\n

In October, we are supporting the awareness campaign \u201cPINK CUBE Test Your Breast\u201d together with EUROPA DONNA Switzerland, the Swiss Cancer League, and many other sponsors.<\/p>\n\n\n\n

The pink container \u201cPink Cube\u201d travels through 11 cantons, where gynecologists will offer interested visitors free consultations and breast examinations. Everyone is invited to visit the Pink Cube.<\/p>\n\n\n\n

Find out more here<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Banner:<\/figure>\n<\/div>\n\n\n\n
\n

Website about breast cancer<\/strong><\/p>\n\n\n\n

Our patient portal, MSD Gesundheit, contains detailed information about breast cancer, including risks and options for prevention, early detection and treatment of breast cancer.<\/p>\n\n\n\n

In addition, the website offers answers to the most frequently asked questions about breast cancer and information on where affected people can get advice and support.<\/p>\n\n\n\n

Visit the MSD Patient Portal<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Pink Ribbon Charity Walk<\/strong><\/p>\n\n\n\n

A special moment for us! Every year, more than 50 colleagues take part in the Pink Ribbon Charity Walk as Team MSD Switzerland.\u00a0<\/p>\n\n\n\n

The solidarity walk celebrates survivors, remembers those that we have lost, raises awareness, and much-needed funds to work towards the vision of zero deaths from breast cancer. <\/p>\n<\/div>\n\n\n\n

\n
\"MSD<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Facts about breast cancer you should know<\/strong><\/p>\n\n\n\n

Breast cancer is the most common cancer in women, accounting for nearly one-third of all cancer diagnoses. In Switzerland, about 6,600 women and 60 men are diagnosed with breast cancer every year and around 1,400 women die from it each year. The rate of disease increases with age. Nevertheless, one in five women is younger than 50 at the time of diagnosis. Mammography is the most important examination for the early detection of breast cancer. It can reveal a tumor before it can be felt or causes any symptoms. Medical societies and the Cancer League recommend that women aged 50 and over have a mammogram every two years. Regular self-examination of the breasts also helps women become more familiar with their bodies and notice any changes that should be checked by a doctor.<\/p>\n\n\n\n

The earlier breast cancer is detected and treated, the better the chances of cure. <\/strong><\/strong>That\u2019s the message we want to get across to everyone!<\/p>\n\n\n\n

<\/div>\n\n\n\n

About our clinical research in Oncology<\/strong><\/p>\n\n\n\n

Did you know that MSD operates one of the world’s largest and fastest growing clinical research programs in oncology? It currently includes more than 1,600 clinical trials. Switzerland is part of this research program. Our team currently coordinates 36 clinical trials in different tumor types (as of 10\/2025). MSD is also one of the leading companies in the research of vaccines against preventable diseases, such as cervical cancer and other HPV-related cancers. In Switzerland, we collaborate with various partners to advance innovative solutions in cancer treatment. In recent years, we have made an important contribution to improving treatment options for cancer patients.<\/p>\n\n\n\n

Find out more about our work here<\/a>.<\/p>\n\n\n\n


<\/p>\n\n\n\n

CH-NON-01897, 10\/2025<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"

In Switzerland, around 6,600 women and 60 men are diagnosed with breast cancer every year. Although new therapies have improved the prognosis of patients with breast cancer, around 1400 women still die from the disease in Switzerland every year. “We stand united for the mothers, sisters, daughters and loved ones impacted by breast cancer and […]<\/p>\n","protected":false},"featured_media":6090,"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[25],"content_topic":[44],"admin_field":[],"class_list":["post-5946","story","type-story","status-publish","has-post-thumbnail","hentry","tag-oncology","content_topic-our-team"],"yoast_head":"\nIn October we support Breast Cancer Awareness Month I MSD Switzerland<\/title>\n<meta name=\"description\" content=\"Especially during Breast Cancer Awareness Month, MSD supports various activities to raise awareness about prevention and early detection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD supports Breast Cancer Awareness Month October\ud83c\udf97\ufe0f\" \/>\n<meta property=\"og:description\" content=\"Especially during Breast Cancer Awareness Month October MSD support various activities to educate about the importance of prevention and early detection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T12:20:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg?w=2899\" \/>\n\t<meta property=\"og:image:width\" content=\"2899\" \/>\n\t<meta property=\"og:image:height\" content=\"1830\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"MSD supports Breast Cancer Awareness Month October\ud83c\udf97\ufe0f\" \/>\n<meta name=\"twitter:description\" content=\"Especially during Breast Cancer Awareness Month October MSD support various activities to educate about the importance of prevention and early detection.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/\",\"url\":\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/\",\"name\":\"In October we support Breast Cancer Awareness Month I MSD Switzerland\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/en\/#website\"},\"datePublished\":\"2025-10-30T12:20:31+00:00\",\"dateModified\":\"2025-10-30T12:20:32+00:00\",\"description\":\"Especially during Breast Cancer Awareness Month, MSD supports various activities to raise awareness about prevention and early detection.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Stories\",\"item\":\"https:\/\/www.msd.ch\/en\/stories-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In October we support Breast Cancer Awareness Month\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/en\/#website\",\"url\":\"https:\/\/www.msd.ch\/en\/\",\"name\":\"msd.ch\",\"description\":\"MSD researches and develops medicines and vaccines to save lives and improve patients' health. In Switzerland, 1000 employees in Lucerne and Zurich are dedicated to this.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In October we support Breast Cancer Awareness Month I MSD Switzerland","description":"Especially during Breast Cancer Awareness Month, MSD supports various activities to raise awareness about prevention and early detection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/","og_locale":"en_US","og_type":"article","og_title":"MSD supports Breast Cancer Awareness Month October\ud83c\udf97\ufe0f","og_description":"Especially during Breast Cancer Awareness Month October MSD support various activities to educate about the importance of prevention and early detection.","og_url":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/","og_site_name":"msd.ch","article_modified_time":"2025-10-30T12:20:32+00:00","og_image":[{"url":"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg?w=2899","width":2899,"height":1830,"type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"MSD supports Breast Cancer Awareness Month October\ud83c\udf97\ufe0f","twitter_description":"Especially during Breast Cancer Awareness Month October MSD support various activities to educate about the importance of prevention and early detection.","twitter_image":"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/09\/DSC00027_FlorianGraf_Photography_MSD_Pink_Ribbon_220925-2-e1664218873475.jpg","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/","url":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/","name":"In October we support Breast Cancer Awareness Month I MSD Switzerland","isPartOf":{"@id":"https:\/\/www.msd.ch\/en\/#website"},"datePublished":"2025-10-30T12:20:31+00:00","dateModified":"2025-10-30T12:20:32+00:00","description":"Especially during Breast Cancer Awareness Month, MSD supports various activities to raise awareness about prevention and early detection.","breadcrumb":{"@id":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/en\/stories\/we-support-breast-cancer-awareness-month\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Stories","item":"https:\/\/www.msd.ch\/en\/stories-archive\/"},{"@type":"ListItem","position":2,"name":"In October we support Breast Cancer Awareness Month"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/en\/#website","url":"https:\/\/www.msd.ch\/en\/","name":"msd.ch","description":"MSD researches and develops medicines and vaccines to save lives and improve patients' health. In Switzerland, 1000 employees in Lucerne and Zurich are dedicated to this.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"extended_data":{"featured_image":"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/10\/Support-banner-stetoscope-e1664808142664.jpg?w=1024","acf_fields":{"mco_page_tracking_data":"","page_text_direction_selection":"ltr","show_section":true,"related_content_section_heading":"","story_one_selection":"select","related_content_item_one":{"ID":1433,"post_author":"974","post_date":"2026-02-20 11:54:29","post_date_gmt":"2026-02-20 10:54:29","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"Oncology\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"We\u2019re working to invent a world where cancer isn\u2019t just treated, but cured \u2014 and even where some types are prevented from happening in the first place.\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":1940,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":\"\",\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Our mission is to deliver breakthrough innovations that extend and improve the lives of people with cancer\",\"_title\":\"mco_title_block_title\",\"description\":\"\\u003cdiv id=\\u0022mco-title-block-block_5e9de3bc8282f\\u0022 class=\\u0022mco-title-block msdberg-block mb-2 aligncenter\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022wrapper\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022mco-title-block-content\\u0022\\u003e\\r\\n\\r\\nWe work to prevent cancer through vaccination and to provide oncologists with treatment options that give their patients a better quality of life and more time.\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\nEveryone knows someone who has been touched by cancer. When a cancer diagnosis happens, what matters most isn't \\u003cem\\u003ewhat\\u003c\/em\\u003e the next scientific breakthrough is - but \\u003cem\\u003ewhen\\u003c\/em\\u003e it will be available to patients in Switzerland.\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Our work in oncology\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group {\"className\":\"stat-group mb-2\"} -->\n<div class=\"wp-block-group stat-group mb-2\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"31\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"clinical trials involving our cancer medicines in Switzerland (as of 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"~250\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"patients currently enrolled in our clinical trials in Switzerland and about 120 patients are actively on study drug (as of 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"\\u0026gt;15\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"different types of cancer are being studied in our clinical trials Switzerland (as of 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"32%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Our focus<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Our company has a long history of bringing forward innovative medicines. In the field of oncology, we focus on immunotherapy, which aims to activate the body's own immune system to fight the tumor. Our relentless commitment to research and development has enabled us to establish an exceptionally broad research program with around 1'600 studies. Switzerland is part of this program, currently conducting 31 <a href=\"https:\/\/www.msd.ch\/en\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\">clinical trials<\/a> in different tumor types (as of 01\/2026). Today, our portfolio includes oncology medicines that treat different cancers and conditions related to cancer treatment.<\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"32%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Access to care<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Improving access to cancer care is our strategic priority. We are working with the entire cancer community to help patients gain access to the oncology medicines that they need and to expand the provision of quality cancer care.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The Swiss Oncology team is:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li>collaborating with authorities and institutions to ensure access to our medicines.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>working on solutions how to continuously improve the support of healthcare professionals and patients in the treatment of cancer.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>interacting with Oncologists, Scientific leaders and patient organizations to gain insight into market and customer needs.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>engages with decision makers to make cancer care in Switzerland even more efficient and solution-oriented.<\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"30px\"} -->\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Progress through partnerships<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>We work with the entire cancer community - advocacy partners, health care providers, government and industry colleagues - all who share our mission to extend and improve the lives of people with cancer.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong>Our focus areas are:<\/strong><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7839,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/06\/education.png\" alt=\"Icon education\" class=\"wp-image-7839\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Information and education<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>We provide information about cancer, prevention and early detection, therapy options, and where patients can get advice and support on various platforms: for cancer patients and their relatives and for medical professionals:<br><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>meine-immuntherapie:<\/strong><br><a href=\"http:\/\/www.meine-immuntherapie.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">for patients undergoing immunotherapy<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>msd-gesundheit.ch:<\/strong> <a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information platform for cancer patients<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>mymsd.ch:<\/strong> <a href=\"https:\/\/www.mymsd.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information platform for medical professionals<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>My Survival Story: <\/strong><a href=\"https:\/\/www.mysurvivalstory.org\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">platform for people who have overcome their cancer<\/a><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7840,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/06\/Prevention.png\" alt=\"Icon prevention\" class=\"wp-image-7840\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Prevention and early detection<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>We work with various patient organizations and support campaigns to raise public awareness about cancer prevention and early detection:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>Derma2go<\/strong>: <a href=\"https:\/\/www.derma2go.com\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">a Swiss teledermatology service that enables skin conditions to be assessed online by specialist physicians and provides a prompt, well-founded diagnosis<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Living with Lung Cancer:\u00a0<\/strong><a href=\"https:\/\/www.leben-mit-lungenkrebs.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">platform for lung cancer patients and their relatives<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>PINK CUBE Test Your Breast:<\/strong>\u00a0<a href=\"https:\/\/www.pinkcube-testyourbreast.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">Initiative to strengthen breast cancer prevention and early detection<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>SGDV <\/strong>Swiss Society of Dermatology and Venereology: <a href=\"https:\/\/www.derma.swiss\/patienten\/hautkrebspraevention\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">national skin cancer campaign for the prevention of skin cancer<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Association for Skin Cancer Research<\/strong>: <a href=\"https:\/\/www.skincancer.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">dedicated to research, prevention, and awareness of skin cancer<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Lunge Zurich Association<\/strong>: <a href=\"https:\/\/lunge-zuerich.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">supports people with lung diseases, provides information on lung health, and advocates for prevention and early detection.<\/a><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7842,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/06\/Cancer-care.png\" alt=\"Icon Cancer Care\" class=\"wp-image-7842\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":3} -->\n<h3 class=\"wp-block-heading\">Improving cancer care<\/h3>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>We support platforms that continuously drive health policy discussions around improving cancer care in Switzerland:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>Gfs Bern:<\/strong> <a href=\"https:\/\/www.msd.ch\/en\/news\/second-cancer-care-survey-of-switzerland-shows-early-detection-and-treatment-majorly-significant\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">regular surveys of the population on the quality of cancer care in Switzerland.<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Oncosuisse:<\/strong> We are a member of the Oncosuisse partner pool and thus actively promote networking in the oncology community with the <a href=\"https:\/\/oncosuisse.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">aim to break down barriers in the system and close gaps<\/a>.<br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Swiss Consumer Forum kf:<\/strong> regular Onco Roundtables with various stakeholders to discuss & find solutions to improve current cancer care in Switzerland.<br><br><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/testimonials-block {\"name\":\"acf\/testimonials-block\",\"data\":{\"media_placement\":\"left\",\"_media_placement\":\"testimonials_block_media_placement\",\"testimonials_posts\":[\"8736\"],\"_testimonials_posts\":\"testimonials_block_posts\"},\"mode\":\"preview\",\"className\":\"mb-1\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\"} -->\n<h2 class=\"wp-block-heading has-text-align-center\"><br>Key therapeutic areas<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:spacer {\"height\":\"30px\"} -->\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5089,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_bladder.png?w=200\" alt=\"\" class=\"wp-image-5089\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Bladder cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/blasenkrebs\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/genitourinary-cancers\/uc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5312,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/03\/Breast_icon-002.png?w=1163\" alt=\"\" class=\"wp-image-5312\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Breast cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/brustkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/tnbc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"width\":\"100px\",\"height\":\"100px\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter is-resized\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2022\/03\/Keytruda_cervical-cancer_icon_msd_green-1.png?w=608\" alt=\"This image has an empty alt attribute; its file name is Keytruda_cervical-cancer_icon_msd_green-1.png\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cervical cancer<br>Endometrial cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gyn-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5086,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_bowel.png?w=200\" alt=\"\" class=\"wp-image-5086\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Colorectal cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/darmkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/colorectal\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":10187,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2026\/01\/Icon_Biliary-Cancer.png?w=240\" alt=\"Icon: Gallbladder cancer and bile duct cancer\" class=\"wp-image-10187\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Gallbladder cancer<br>Bile duct cancer<br><\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/gallenblasenkrebs-und-gallengangskrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5090,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_headneck.png?w=200\" alt=\"\" class=\"wp-image-5090\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Head and neck cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/kopf-und-halskrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/head-and-neck-squamous-cell-carcinoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5088,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_lymphoma.png?w=200\" alt=\"\" class=\"wp-image-5088\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Hodgkin-Lymphoma<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/hodgkin-lymphom\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/classical-hodgkin-lymphoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5091,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_kidney.png?w=200\" alt=\"\" class=\"wp-image-5091\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Kidney cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/nierenkrebs\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/genitourinary-cancers\/rcc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5078,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_lung.png?w=200\" alt=\"\" class=\"wp-image-5078\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Lung cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/lungenkrebs\" target=\"_blank\" rel=\"noreferrer noopener\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/tc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":5087,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2021\/12\/oncology_melanoma.png?w=200\" alt=\"\" class=\"wp-image-5087\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Melanoma<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/melanom\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/melanom\/\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7410,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2023\/04\/Prostate-Cancer-Icon.png\" alt=\"\" class=\"wp-image-7410\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Prostate Cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/prostatakrebs\">Information for patients<\/a><br><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":9284,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-full is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2025\/08\/Icon-Magenkrebs1.png\" alt=\"\" class=\"wp-image-9284\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Stomach Cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/magenkrebs\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.msd-gesundheit.ch\/de\/krebs\/magenkrebs\">Information for patients<\/a><br><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/gastric\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.mymsd.ch\/de\/products\/keytruda\/indikationen\/gastrointestinal-cancers\/gastric\/\" target=\"_blank\" rel=\"noreferrer noopener\">Information for HCPs<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Learn more about our commitment to fight cancer\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/featured-stories-block-e1 {\"name\":\"acf\/featured-stories-block-e1\",\"data\":{\"content_selection\":\"manual\",\"_content_selection\":\"mco_featured_stories_e1_block_content_selection\",\"story_one\":7480,\"_story_one\":\"mco_featured_stories_e1_block_story_one\",\"story_two\":8449,\"_story_two\":\"mco_featured_stories_e1_block_story_two\",\"story_three\":7949,\"_story_three\":\"mco_featured_stories_e1_block_story_three\",\"story_four\":6999,\"_story_four\":\"mco_featured_stories_e1_block_story_four\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00473, 02\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Oncology","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"oncology","to_ping":"","pinged":"","post_modified":"2026-02-20 11:54:42","post_modified_gmt":"2026-02-20 10:54:42","post_content_filtered":"","post_parent":25,"guid":"https:\/\/vip2-msd.com\/germany\/?page_id=1433","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_two_selection":"select","related_content_item_two":{"ID":2759,"post_author":"974","post_date":"2026-03-31 21:24:43","post_date_gmt":"2026-03-31 19:24:43","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"MSD clinical studies in Switzerland\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"\\u0022Clinical studies are the key to gaining new knowledge about the diagnosis and treatment of diseases. We're proud to be contributing to this effort in Switzerland.\\u0022\\r\\n\\r\\n\\u003cem\\u003eKlaudia Georgi, Sr. Director Clinical Research MSD Switzerland \\u0026amp; Serbia\\u003c\/em\\u003e\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":2760,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":{\"title\":\"Basic knowledge of clinical studies\",\"url\":\"https:\/\/www.msd.ch\/en\/home\/research\/clinical-trials\/\",\"target\":\"\"},\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"mco_hero_block_button_cta_aria_label\":\"\",\"_mco_hero_block_button_cta_aria_label\":\"mco_hero_block_button_cta_aria_label\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Our work by the numbers\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group -->\n<div class=\"wp-block-group\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"40\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"ongoing clinical studies in Switzerland (as of 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"10\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"MSD first-in-class medicines and vaccines approved in Switzerland since 2010 (as of 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"173\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"million Swiss francs invested in research since 2012 (as of 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"preview\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:acf\/content-block {\"name\":\"acf\/content-block\",\"data\":{\"maintain_image_aspect_ratio\":\"0\",\"_maintain_image_aspect_ratio\":\"content_block_maintain_image_aspect_ratio\",\"negative_style\":\"0\",\"_negative_style\":\"content_block_negative\",\"content_selection\":\"static\",\"_content_selection\":\"content_selction_method\",\"content_block_image\":10399,\"_content_block_image\":\"content_block_image\",\"content_block_heading\":\"MSD Switzerland's clinical research is coordinated at our site in R\u00f6sslimatt in Lucerne\",\"_content_block_heading\":\"content_block_heading\",\"heading_level\":\"h3\",\"_heading_level\":\"content_block_heading_level\",\"content_block_body\":\"\",\"_content_block_body\":\"content_block_body\",\"content_block_cta\":{\"title\":\"Our sites\",\"url\":\"https:\/\/www.msd.ch\/en\/home\/about-us\/sites\/\",\"target\":\"_blank\"},\"_content_block_cta\":\"content_block_cta\",\"content_block_aria_label\":\"\",\"_content_block_aria_label\":\"content_block_aria_label\",\"content_block_cta_button_style\":\"\",\"_content_block_cta_button_style\":\"content_block_cta_button_style_cf4f3fd32dc26ec4ba7a6c14e51289c8\",\"content_block_optional_cta\":\"\",\"_content_block_optional_cta\":\"content_block_optional_cta\",\"content_block_optional_cta_aria_label\":\"\",\"_content_block_optional_cta_aria_label\":\"content_block_optional_cta_aria_label\",\"content_block_optional_cta_button_style\":\"\",\"_content_block_optional_cta_button_style\":\"content_block_optional_cta_button_style_d7b3517ac72218a3fb8daa4bc7def7a4\",\"content_block_optional_tag\":\"\",\"_content_block_optional_tag\":\"content_block_optional_tag\",\"content_block_video\":\"\",\"_content_block_video\":\"content_block_video\",\"content_media_position\":\"left\",\"_content_media_position\":\"content_media_position\",\"brightcove_account_id\":\"\",\"_brightcove_account_id\":\"bright_cove_account_id\",\"content_block_video_accessible_name\":\"\",\"_content_block_video_accessible_name\":\"content_block_video_accessible_name\",\"content_block_play_button_accessible_name\":\"\",\"_content_block_play_button_accessible_name\":\"content_block_play_button_accessible_name\",\"content_block_popup_accessible_name\":\"\",\"_content_block_popup_accessible_name\":\"content_block_popup_accessible_name\",\"content_block_popup_close_button_accessible_name\":\"\",\"_content_block_popup_close_button_accessible_name\":\"content_block_popup_close_button_accessible_name\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":1} -->\n<h1 class=\"wp-block-heading has-text-align-center\">MSD's clinical study program in Switzerland (as of 01\/2026)<\/h1>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\"} -->\n<p class=\"has-text-align-center\">(published on <a href=\"http:\/\/www.clinicaltrials.gov\/\">www.clinicaltrials.gov<\/a>)<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":10149,\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full\"><img src=\"https:\/\/www.msd.ch\/en\/wp-content\/uploads\/sites\/42\/2026\/01\/2026-01-MSD-Map-Clinical-Study-Program-Switzerland.png\" alt=\"Map: MSD Switzerland clinical trial sites (as of 01\/2026)\" class=\"wp-image-10149\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"In the field of General Medicine\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Pulmonary Disease\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-5475-013 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease\\r\\n\\r\\nStudy centers: St. Gallen, Zurich, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7962-038 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH\\r\\n\\r\\nStudy center: Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"In the field of Immunology\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Intestinal Disease\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-7240-001 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis\\r\\n\\r\\nStudy centers: Bern, St. Gallen, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7240-008 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease\\r\\n\\r\\nStudy centers: Basel, Bern, St. Gallen, Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"In the field of Infectiology\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"HIV\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8527-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nPhase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis\\r\\n\\r\\nStudy centers: Basel, Bern, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-051 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591A-053 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants\\r\\n\\r\\nStudy centers: Basel, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-054 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591B-060 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lugano\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"In the field of Oncology\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Bladder Cancer\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-676\/KEYNOTE-676 \u2013 recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"Blood Cancer (Hematologic Malignancies)\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1026-003 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies\\r\\n\\r\\nStudy centers: Bellinzona, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2140-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)\\r\\n\\r\\nStudy centers: Baden, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4280A-008 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)\\r\\n\\r\\nStudy centers: Bellinzona\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"Breast Cancer\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer\\r\\n\\r\\nStudy centers: Basel, Thun, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-012 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery\\r\\n\\r\\nStudy centers: Chur, Fribourg, Geneva, Thun, Zurich\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"Esophageal cancer\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-3475-06B \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06C \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06D \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06E \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06F \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F\\r\\n\\r\\nStudy centers: Chur, Geneva\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"Gastrointestinal Cancer\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1022-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Geneva, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003e\\u003cstrong\\u003eMK-5909-005 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Basel, Zurich, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-9999-U02A \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Bellinzona, Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"Gynecological cancers\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-005 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-020 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer\\r\\n\\r\\nStudy centers: Basel, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-021 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Geneva, Winterthur\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"Head and Neck Cancer\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\nMK-3475-689\/KEYNOTE-689 - recruitment closed\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Geneva\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"Kidney Cancer (Renal Cell Carcinoma)\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-6482-011 \u2013 recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Chur, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"Lung Cancer\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1084-007 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)\\r\\n\\r\\nStudy centers: Fribourg, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-019 \u2013\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003erecruitment open\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery\\r\\n\\r\\nStudy centers: Lausanne, Fribourg, Frauenfeld, Chur\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-091\/KEYNOTE-091 \u2013\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced \u2013 recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-B98 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: St. Gallen\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"Melanoma (skin cancer)\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-054 \/ KEYNOTE-054 \u2013\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced \u2013 recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-716\/KEYNOTE-716 \u2013\u00a0\\u003cspan class=\\u0022green_text\\u0022\\u003erecruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"Prostate cancer\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2400-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\\r\\n\\r\\nStudy centers: Aarau, Basel, Fribourg, Geneva, Zurich\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"Solid Tumors\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-0472-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.\\r\\n\\r\\nStudy centers: Geneva, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-1084-001 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\nA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, St. Gallen\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-587\/KEYNOTE-587 \u2013 recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eLong-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Basel, Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4884-001 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, Lausanne, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-7339-002 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Bellinzona\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":12,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>For an overview of studies throughout Switzerland that are looking for participants, visit <a href=\"https:\/\/www.humanforschung-schweiz.ch\/en\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:acf\/featured-banner-block {\"name\":\"acf\/featured-banner-block\",\"data\":{\"mco_featured_banner_negative\":\"1\",\"_mco_featured_banner_negative\":\"mco_featured_banner_negative_294ytohe\",\"image\":2806,\"_image\":\"mco_featured_banner_block_image\",\"title\":\"We strive to provide hope to people with cancer\",\"_title\":\"mco_featured_banner_block_title\",\"description\":\"We invest in the development of innovative oncological drugs to provide hope to people with cancer.\",\"_description\":\"mco_featured_banner_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_featured_banner_block_content_label\",\"cta_one\":{\"title\":\"Learn more\",\"url\":\"https:\/\/www.msd.ch\/en\/home\/about-us\/areas-of-focus\/oncology\/\",\"target\":\"_blank\"},\"_cta_one\":\"mco_featured_banner_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_featured_banner_block_cta_two\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Clinical trials in Switzerland","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"clinical-trials-in-switzerland","to_ping":"","pinged":"","post_modified":"2026-03-31 21:24:55","post_modified_gmt":"2026-03-31 19:24:55","post_content_filtered":"","post_parent":10099,"guid":"https:\/\/www.msd.ch\/en\/?page_id=2759","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_three_selection":"select","related_content_item_three":false,"scroll-to-top":false,"subheader_title":"Did you know breast cancer is the most common cancer in women? At MSD, we show solidarity with those facing breast cancer and do everything we can to support further advances to help fighting the disease. Especially during Breast Cancer Awareness Month October we support various activities to educate about the importance of prevention and early detection. Learn more about our commitment.","secondary_image":false,"video_hosting_selection":"youtube","youtube_url":"","primary_cta":"Read more","secondary_cta":"","mcc_page_job_number":"","show_image_captions":false,"heading_level":"","related_content_item_one_aria_label":"","related_content_item_two_aria_label":"","video_accessible_name":"","primary_cta_aria_label":"","secondary_cta_aria_label":""}},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/story\/5946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/story"}],"about":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/types\/story"}],"version-history":[{"count":109,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/story\/5946\/revisions"}],"predecessor-version":[{"id":9932,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/story\/5946\/revisions\/9932"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/media\/6090"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/media?parent=5946"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/tags?post=5946"},{"taxonomy":"content_topic","embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/content_topic?post=5946"},{"taxonomy":"Admin Field","embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/admin_field?post=5946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}